A non-anticoagulant heparin-like snail glycosaminoglycan promotes healing of diabetic wound

Diabetic foot ulcer (DFU) is a common high-risk complication in patients with diabetes mellitus, but current drugs and therapies in management of this disease cannot meet the urgent clinical needs. In this study, a snail glycosaminoglycan (SGAG) from the cultured China white jade snail was purified and structurally clarified. This snail glycosaminoglycan is a regular sulfated polysaccharide, composed of iduronic acid (IdoA) and N-acetyl-glucosamine (GlcNAc) with the repeating sequence of ?4)-?-GlcNAc (1?4)-?-IdoA2S (1?. The biological assays showed that SGAG had no anticoagulant activity for lacking speci?c heparin pentasaccharide sequence. The pharmacological experiments suggested that SGAG markedly accelerated the healing of full-thickness wounds in diabetic mice skin. Histologic and immunohistochemical analysis revealed that SGAG treatment alleviated the inflammation and dermal edema, and promoted angiogenesis. This is the first report applying the snail glycosaminoglycan to favor diabetic wound healing.

» Author: Yuebo Wu, Zhipeng Zhou, Lan Luo, Maixian Tao, Xiao Chang, Lian Yang, Xingyong Huang, Lin Hu, Mingyi Wu

» More Information

« Go to Technological Watch



This project has received funding from the Bio-Based Industries Joint Undertaking under the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 745828